Verve Therapeutics Inks 105K-SF Life Science Lease in Fenway
Biotech firm Verve Therapeutics has signed a 10-year, 105,000-square-foot lease at 201 Brookline Ave. in the Fenway neighborhood of Boston.
The under-construction 201 Brookline will be a 14-story tower spanning approximately 500,000 square feet and is being developed by Samuels & Associates as well as Alexandria Real Estate Equities. Verve Therapeutics is focused on developing gene-editing medicine targeting cardiovascular disease. Verve’s lease includes up to $21M in tenant improvement funds and three months’ free rent, according to reports.
Other recent lease signings at the property include Kendall Square-based Tango Therapeutics for 65,000 square feet and venture capital firm Third Rock Ventures for 25,000 square feet.
David Cohen is Southeast Editorial Director at Connect Commercial Real Estate. David is a media veteran with more than 10 years of experience in journalism, copywriting and communications across a variety of roles. He is responsible for covering commercial real estate news and trends in the Southeast, Florida, Washington D.C. and Boston at Connect CRE as well as specializing in the Student Housing sector.
Prior to joining Connect, David was the editor of Northeast Real Estate Business magazine and Student Housing Business magazine at France Media as well as spending time freelancing for ESPN and the Associated Press in the fast-paced field of live sports event production. He is also an owner and investor in multifamily real estate in Atlanta, GA.
David currently resides in Atlanta and graduated from the College of Communication & Information at the University of Tennessee Knoxville.